title: Low-dose aspirin and risk of cataract and subtypes in a randomized trial of U.S. physicians.
abstract: OBJECTIVE
  To examine whether low-dose aspirin (325 mg on alternate days) reduces the risk of age-related cataract and subtypes. This report extends previous findings, including both subtypes and additional newly identified incident cases since the earlier report.
  
  
  METHODS
  All 20,979 participants in the Physicians' Health Study, a randomized trial of aspirin and beta-carotene among U.S. male physicians age 40-84 in 1982, who did not report cataract at baseline were included. Average follow-up was five years. The main outcome measure was incident, age-related cataract responsible for a reduction in best-corrected visual acuity to 20/30 or worse, based on self-report confirmed by medical record review.
  
  
  RESULTS
  501 age-related cataracts were diagnosed during follow-up, including 416 with nuclear sclerosis and 212 with a posterior subcapsular component; 318 cataracts progressed to surgical extraction. Overall, there were 245 cataracts in the aspirin group and 256 in the placebo group (relative risk [RR], 0.94; 95% confidence interval [CI], 0.79 to 1.13; P = 0.52). Cataract extractions were 19% less frequent in the aspirin than in the placebo group (RR, 0.81; 95% CI, 0.65 to 1.01; P = 0.06). In subgroup analyses of subtypes, aspirin takers had a lower risk of posterior subcapsular cataract (RR, 0.74; 95% CI, 0.57 to 0.98; P = 0.03) but not nuclear sclerosis (RR, 0.96; 95% CI, 0.79 to 1.16; P = 0.65) cataract.
  
  
  CONCLUSIONS
  Overall, these randomized trial data tend to exclude a large benefit of five years of low-dose aspirin therapy on cataract development and extraction. The data are compatible with a modest benefit on cataract extraction for this duration of aspirin therapy. Subgroup analyses raise the possibility of a modest, but potentially important, protective effect of aspirin on posterior subcapsular cataract, a particularly disabling subtype.
authors.affiliation: Division of Preventive Medicine, Harvard Medical School, Boston, MA, USA.
authors.forename: W G
authors.initials: WG
authors.lastname: Christen
authors.forename: J E
authors.initials: JE
authors.lastname: Manson
authors.forename: R J
authors.initials: RJ
authors.lastname: Glynn
authors.forename: U A
authors.initials: UA
authors.lastname: Ajani
authors.forename: D A
authors.initials: DA
authors.lastname: Schaumberg
authors.forename: R D
authors.initials: RD
authors.lastname: Sperduto
authors.forename: J E
authors.initials: JE
authors.lastname: Buring
authors.forename: C H
authors.initials: CH
authors.lastname: Hennekens
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D002386:Cataract / Q000453:epidemiology / Q000517:prevention & control*; D002387:Cataract Extraction / Q000706:statistics & numerical data; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010820:Physicians; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin